Skip to content
Screener

Perspective Therapeutics CATX Q4 2024 Annual earnings

Reported March 26, 2025 · After market close

Revenue$234.0KMiss by $43.3K
EPS-$0.25Beat by $0.01
Revenue estimate$277.3K
EPS estimate-$0.26

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$62.1K
EPS estimate-$0.24

Financials

Q4 2024

Income statement

See full
Operating income-$45.0M-285%
Net income-$40.2M-62.8%
EPS (diluted)-$0.61+33.0%

Balance sheet

See full
Cash & equivalents$61.6M+567%
Total debt$4.0M+60.3%
Total equity$290.7M+287%
Total assets$341.1M+248%

Cash flow

See full
Operating cash flow-$26.6M-195%
CapEx$14.6M+16,320%
Free cash flow-$41.2M-353%

Valuation & ratios

Valuation

as of 12/31/24
See full
Market cap$215.6M+91.2%
Enterprise value$158.03M+49.0%

Returns & leverage

See full
Return on equity-43.3%-12.3pp
Debt / equity0×0.0×
Current ratio12.7×+11.6×

FAQ

When did Perspective Therapeutics report Q4 2024 earnings?
Perspective Therapeutics (CATX) reported Q4 2024 earnings on March 26, 2025 after market close.
What were Perspective Therapeutics's Q4 2024 revenue and EPS?
Perspective Therapeutics reported revenue of $234.0K and eps of $-0.25 for Q4 2024.
Did Perspective Therapeutics beat estimates in Q4 2024?
Revenue missed the consensus estimate of $277.3K by $43.3K. EPS beat the consensus estimate of $-0.26 by $0.01.
Where can I find Perspective Therapeutics's Q4 2024 SEC filings?
You can read the 8-K earnings release (0000950170-25-045227) and the 10-K periodic report (0000950170-25-045242) directly on SEC EDGAR. The filing index links above go to sec.gov.